RO8191
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
EC50: 0.2 μM for anti-HCV activity
RO8191 is an IFN-α receptor 2 agonist.
Most acute hepatitis C virus (HCV) infections become chronic and some progress to liver cirrhosis or hepatocellular carcinoma, with thes tandard therapy involving an interferon (IFN)-α-based regimen.
In vitro: Previous study found that RO8191had remarkable anti-HCV activity. More importantly, RO8191 exerted its antiviral activity by directly interacting with the type I IFN receptor to drive IFN-stimulated genes (ISG) expression, which then induced the antiviral response of innate immune system. Previous researchers conducted a systematic structure activity relationship (SAR) study on RO8191, and although more than 100 analogues were synthesized, none of the analogues displayed improved anti-HCV activity, suggesting that RO8191 displayed a relative narrow window of SAR [1].
In vivo: A previous study evaluated the effects of RO8191 on IFN signaling in mice. Results showd that the antiviral genes were significantly induced in the livers of mice treated with RO8191. In addition, genes that had previously been reported to be induced by IFN-b in mouse liver were also induced in the livers of RO8191-treated mice. This study also measured inflammatory cytokine and chemokine expressions, and RO8191 did not significantly induce the expression of these genes. To evaluate the in-vivo anti-HCV activity of RO8191, RO8191 was orally administered to HCV-infected humanized liver mice, and the results showed that RO8191 was able to reduce HCV titer in vivo [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Wang H, Wang S, Cheng L, Chen L, Wang Y, Qing J, Huang S, Wang Y, Lei X, Wu Y, Ma Z, Zhang L, Tang Y. Discovery of Imidazo[1,2-α][1,8]naphthyridine Derivatives as Potential HCV Entry Inhibitor. ACS Med Chem Lett. 2015 Jul 27;6(9):977-81.
[2] Konishi H et al. An orally available, small-molecule interferon inhibits viral replication. Sci Rep. 2012;2:259.
Physical Appearance | A crystalline solid |
Storage | Store at 2-8°C |
M.Wt | 373.2 |
Cas No. | 691868-88-9 |
Formula | C14H5F6N5O |
Synonyms | RO4948191 |
Solubility | ≤0.1mg/ml in DMSO;0.5mg/ml in dimethyl formamide |
Chemical Name | 8-(1,3,4-oxadiazol-2-yl)-2,4-bis(trifluoromethyl)-imidazo[1,2-a][1,8]naphthyridine |
SDF | Download SDF |
Canonical SMILES | FC(C1=CC(C(F)(F)F)=C2C(N3C(C=C2)=NC(C4=NN=CO4)=C3)=N1)(F)F |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |